SNPX: Multiplikator rega marang pendapatan Synaptogenix Inc.
The success of briostatin-1 will provide Synaptogenix, Inc. (SNPX) with absolute pricing power due to unique synapse regeneration. The price-to-sales multiple allows for an assessment of the business's market value, with the 0.00 mark indicating the current metric level. Primary threats are linked to potential trial failures and a dependence on investment. The operating model relies on external contractors to conduct clinical trials.
Neurotrope (SNPX) - rincian metrik lan laporan keuangan
- kuotasi saiki lan rata-rata prakiraan nilai:
- informasi kapitalisasi pasar:
- data kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Koefisien Total Utang marang Modal Synaptogenix, Inc.|SNPX - Rasio utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal Synaptogenix, Inc|SNPX - Gunggung utang perusahaan|Rasio utang marang aset resik Neurotrope|SNPX - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Synaptogenix|Rasio likuiditas darurat synaptogen.com
- data bathi lan kelipatan valuasi:
SNPX - Bathi resik|Bathi mangsa ngarep Synaptogenix, Inc.|SNPX - Koefisien rega marang bathi|Kapitalisasi marang proyeksi bathi Synaptogenix Inc.|SNPX - Rasio rega marang bathi tumrap wutah|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Neurotrope|SNPX - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone 12 wulan pungkasan Synaptogenix|SNPX - Bathi saben saham sajrone rolas wulan pungkasan|Dinamika bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan synaptogen.com|SNPX - Wutah bathi resik saben saham ing taun iki|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Synaptogenix, Inc.
- data total pendapatan lan volume dodolan:
Ringkesan analitik perusahaan:synaptogen.com, SNPX
A fundamental valuation of Synaptogenix, Inc. (SNPX) through risk minimization requires an analysis of capitalization efficiency relative to revenue, which is particularly critical given the high costs of laboratory environmental upgrades and energy conservation. The ratio of market value to sales volume, reflected in the price-to-sales multiple, demonstrates how much an investor is willing to pay per unit of revenue, determining the degree of overvaluation or the growth potential of the company's assets.
Perusahaan pesaing
BIIB - Rega marang dodolan|Multiplikator P/S NBIX (Neurocrine Biosciences, Inc.)|Multiplikator rega marang pendapatan Regencell Bioscience Ltd|Axsome Therapeutics Inc - Multiplikator P/S|Rega marang dodolan ACADIA Corp|Xenon Pharmaceuticals (XENE) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan VKTX|SUPN (Supernus) - Multiplikator P/S|Catalyst Pharma (CPRX) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan DNLI (Denali Therapeutics Inc)|Harmony Corp - Rasio kapitalisasi marang pendapatan|Biohaven Ltd. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan AMLX|Trevi Therapeutics, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Praxis Precision Medicines Inc PRAX|Anavex Corp (AVXL) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan CBLL|PRTA (Prothena Biosciences) - Multiplikator P/S|Kapitalisasi marang pendapatan Alector Therapeutics (ALEC)|Kapitalisasi marang pendapatan ANNX (Annexon)|Koefisien rega marang pendapatan omeros.com|Rasio rega marang pendapatan Neurogene Corp NGNE|Koefisien rega marang pendapatan AC Immune Inc (ACIU)|VYGR - Rasio rega marang pendapatan|NMRA (neumoratx.com) - Rasio kapitalisasi marang pendapatan|Scilex (SCLX) - Rasio rega marang pendapatan|Rasio rega marang dodolan TVGN (Tevogen Bio Holdings Inc.)|Kapitalisasi marang pendapatan ACOG|Rasio kapitalisasi marang pendapatan CGTX (Cognition Therapeutics Inc.)|Rasio rega marang pendapatan Inhibikase Therapeutics (IKT)|cassavasciences.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Rega marang dodolan|VTGN: Kapitalisasi marang pendapatan|OVID - Multiplikator P/S|Acumen Pharmaceuticals (ABOS) - Rasio rega marang pendapatan|cervomed.com - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Alterity Therapeutics Ltd.|Rega marang dodolan Clene Nanomedicine CLNN|Rasio rega marang pendapatan PepGen Inc. (PEPG)|Koefisien rega marang pendapatan Jupiter Neurosciences, Inc.|Relmada Therapeutics - Kapitalisasi marang pendapatan|annovisbio.com (ANVS) - Rega marang dodolan|GRCE - Rasio rega marang pendapatan|AIFF (Firefly Neuroscience, Inc.) - Rasio kapitalisasi marang pendapatan|KLTO: Multiplikator P/S|NeuroSense Therapeutics Ltd. (NRSN) - Multiplikator P/S|Rasio rega marang pendapatan Reviva Pharmaceuticals|MetaVia, Inc. - Rasio rega marang dodolan|Kapitalisasi marang pendapatan NRXS (NeurAxis)|Kapitalisasi marang volume dodolan HSDT|Rasio rega marang pendapatan Passage Bio PASG|Neuphoria Therapeutics, Inc. (NEUP) - Rega marang dodolan|Minerva Neurosciences - Multiplikator P/S|Multiplikator rega marang pendapatan athira.com (ATHA)|ADXN: Multiplikator P/S|Rega marang dodolan Alzamend Neuro (ALZN)|Rasio rega marang pendapatan Cyclerion Therapeutics Inc.|Rasio kapitalisasi marang pendapatan PTIX (Protagenic)|Multiplikator P/S KTTA|Koefisien rega marang pendapatan cortigent.com|Avenue Therapeutics, Inc. - Kapitalisasi marang pendapatan|BCLI: Rasio kapitalisasi marang pendapatan|CARA: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CHRO (Chromocell)|ELYM: Multiplikator P/S|ITCI - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Longboard Pharmaceuticals, Inc.|Rasio kapitalisasi marang pendapatan MRNS (Marinus Pharmaceuticals Inc)|Multiplikator P/S NKGN|Kapitalisasi marang pendapatan NeuroBo Pharma NRBO|Sage Therapeutics, Inc. - Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan trevena.com (TRVN)|VIGL - Rasio rega marang pendapatan|Koefisien rega marang pendapatan anewmeds.com WENA|Cerevel (CERE) - Rasio rega marang pendapatan
